Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria

The Journal of Infectious Diseases
H F GuiotR van Furth

Abstract

To reduce the frequency and severity of bacterial infection, selective antimicrobial modulation (SAM) was applied in 39 patients with severely decreased host defense mechanisms. The objective was to eliminate potentially pathogenic aerobic microorganisms with minimal disturbance of the normal anaerobic bacterial flora. Elimination of potentially pathogenic aerobic microorganisms was easily accomplished in patients not infected at hospitalization. The anaerobic flora seemed to be undisturbed, and selection of or overgrowth with resistant microorganisms did not occur. The microbiologic results of the SAM regimen correlated with the incidence of infection. Only three major infections occurred in 23 patients who were free of potentially pathogenic microorganisms; 10 major infections occurred in 16 patients who were not free of potential pathogens. Seven of these 10 infections were present at hospitalization. The incidence of major infections was 47% in the patients on the SAM regimen and 82% in a group of control patients with a similar risk of infection.

Citations

Sep 1, 1986·Digestive Diseases and Sciences·G L Simon, S L Gorbach
Jan 1, 1979·Infection·J W van der MeerM Boekhout
Feb 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S L GorbachN V Jacobus
Feb 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D van der Waaij
Feb 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C L WellsR L Simmons
Jan 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R van Furth, H F Guiot
Feb 21, 1986·Pharmaceutisch Weekblad. Scientific Edition·R P Mouton
Jun 1, 1987·European Journal of Clinical Microbiology·M P WilhelmJ E Rosenblatt
Jan 1, 1984·Antonie van Leeuwenhoek·M P Hazenberg, A M Pennock-Schröder
Feb 28, 1987·Lancet·J W GratamaJ M Vossen
Aug 1, 1984·The Journal of Hygiene·M P HazenbergJ P Van de Merwe
Dec 1, 1992·Epidemiology and Infection·H F Guiot, R van Furth
Nov 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J W GratamaI Ernberg
Jan 1, 1992·Critical Reviews in Food Science and Nutrition·C J Rumney, I R Rowland
May 1, 1984·British Journal of Haematology·J W GratamaJ G Eernisse
Jun 1, 1983·Antonie van Leeuwenhoek·M P HazenbergJ P Van de Merwe
Apr 1, 1990·Current Problems in Surgery·T E Starzl, A J Demetris
Jan 1, 1989·Scandinavian Journal of Infectious Diseases. Supplementum
Oct 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P GinésJ M Salmerón
Nov 1, 1990·JPEN. Journal of Parenteral and Enteral Nutrition·D C BelknapD J Flournoy
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Anat Gafter-GviliLeonard Leibovici
Jul 15, 1986·Cancer·J Skelton, P A Pizzo
Oct 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J C Hoefs
Apr 1, 1992·The British Journal of Surgery·G W TetterooH A Bruining
Dec 8, 1988·The New England Journal of Medicine·O T TerpstraC B Reuvers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.